Blood biomarkers for Alzheimer’s disease diagnosis in the context of disease‐modifying treatment: a cost‐utility analysis
Sandar Aye, Ron Handels, Bengt Winblad, Linus Jönsson · 2025
Read Blood biomarkers for Alzheimer’s disease diagnosis in the context of disease‐modifying treatment: a cost‐utility analysis by Sandar Aye, Ron Handels, Bengt Winblad, Linus Jönsson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11716606.txt.
Description
Blood tests that flag the brain changes of Alzheimer's disease could reshape how the illness is confirmed. That matters now that treatments aim to slow it. Aye, Handels, Winblad, and Jönsson model the money and health effects of using blood biomarkers in two places. In primary care, the test would decide who gets referred onward. In memory clinics, it would decide who needs a spinal fluid test. Their model follows patients through diagnosis and treatment over thirty years.
Used in primary care, the blood test raised referrals by eight percent and true diagnoses by about ten percent. The cost per year of healthy life gained was modest. Used in the memory clinic, it cut invasive spinal tests and saved money up front but missed some true cases, costing health in the long run. The study suggests the blood test earns its place early in the pathway.
Catalog record
| CREATOR | Sandar Aye, Ron Handels, Bengt Winblad, Linus Jönsson |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |